[CCAFU Recommendations 2013: Bladder carcinoma].

Area of Science:

• Uro-oncology
• Bladder Cancer Management
• Clinical Guidelines

Context:

• The French Urological Association Cancer Committee sought to update existing guidelines for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).
• A comprehensive literature review from 2010-2013 informed the evidence-based recommendations.
• Current diagnostic and therapeutic approaches were evaluated to refine patient care pathways.

Purpose:

• To provide updated, evidence-based guidelines for the diagnosis, treatment, and follow-up of NMIBC and MIBC.
• To incorporate recent advancements in diagnostic tools and therapeutic options.
• To improve the stratification of patients based on risk of recurrence and progression.

Summary:

• Diagnosis of NMIBC relies on cystoscopy and deep tumor resection, with fluorescence and second-look procedures enhancing accuracy. The EORTC score aids in risk stratification for adjuvant therapies like chemotherapy or intravesical BCG.
• For MIBC, CT scans are standard for staging; cystectomy with lymph node resection is the gold standard for non-metastatic disease. Neoadjuvant chemotherapy is recommended for advanced stages, and platinum-based chemotherapy is the first-line treatment for metastatic MIBC.
• Guidelines recommend orthotopic bladder substitution or ureterostomy for urinary diversion and highlight vinfluvine as a validated second-line treatment for metastatic MIBC.

Impact:

• These updated guidelines aim to enhance patient management, diagnosis, and treatment efficacy for both NMIBC and MIBC.
• Implementation is expected to improve clinical decision-making and patient outcomes in bladder cancer care.
• The guidelines provide a framework for standardized, evidence-based care across different stages of bladder cancer.